Table 5.
Baseline respiratory pharmacotherapies among patients with COPD
| n | % of total 59,906 | % of treated 36,285 | |
|---|---|---|---|
| Treated1 | 36,285 | 60.6 | 100.0 |
| Inhaled corticosteroid+long-acting | 449 | 0.7 | 1.2 |
| beta-agonist combination, any Inhaled corticosteroid+long-acting | 261 | 0.4 | 0.7 |
| beta-agonist combination 250/50 Inhaled corticosteroid | 11,177 | 18.6 | 30.8 |
| Short-acting beta-agonist | 32,629 | 54.5 | 89.9 |
| Long-acting beta-agonist | 2,176 | 3.6 | 6.0 |
| Short- or long-acting anticholinergic | 13,493 | 22.5 | 37.2 |
| Untreated2 | 23,621 | 39.4 | na |
Notes:
1
Defined as receiving medications in these drug class groups within 90 days before or after the index date.
2
Not treated with any of these groups.
Abbreviation: COPD, chronic obstructive pulmonary disease.